Carla Martín Cortázar

Dr. Carla Martín Cortázar


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
CFCristina Ferreras
Cristina Ferreras
LFLucía Fernández
Lucía Fernández
LCLaura Clares-Villa
Laura Clares-Villa
MIMarta Ibáñez-Navarro
Marta Ibáñez-Navarro
CCCarla Martín Cortázar
Carla Martín Cortázar
Antonio Pérez MartínezAntonio Pérez Martínez
Antonio Pérez Martínez
Central nervous system (CNS) tumours comprise 25% of the paediatric cancer diagnoses and are the leading cause of cancer-related death in children. Current treatments for paediatric CNS tumours are far from optimal and fail for those that relapsed or are refractory to treatment. Besides, long-term sequelae in the developing brain make it mandatory to find new innovative approaches. Chimeric antigen receptor T cell (CAR T) therapy has increased survival in patients with B-cell malignancies, but the intrinsic biological characteristics of CNS tumours hamper their success. The location, heterogeneous antigen expression, limited infiltration of T cells into the tumour, the selective trafficking provided by the blood–brain barrier, and the immunosuppressive tumour microenvironment have emerged as the main hurdles that need to be overcome for the success of CAR T cell therapy. In this review, we will focus mainly on the characteristics of the deadliest high-grade CNS paediatric tumours (medulloblastoma, ependymoma, and high-grade gliomas) and the potential of CAR T cell therapy to increase survival and patients’ quality of life.